This article was originally published in The Tan Sheet
Tampa, Fla.-based Calgenex announces the launch of Dermalleve, an over-the-counter topical treatment for psoriasis, eczema and seborrheic dermatitis that combines 1% hydrocortisone with natural ingredients to moisturize and nourish skin, the firm states Sept. 27. The product contains natural ingredients such as alpha-hydroxy acids, skin-nourishing nutrients and skin conditioners such as aloe vera, shea butter, vitamin E, jojoba oil and silicone. The product "helps to gently remove dead skin cells while skin-nourishing nutrients, conditioners and moisturizers support healthy skin," Calgenex says. Demalleve also applies easily and evenly because it has the consistency of a lubricant unlike other anti-itch creams which can be too thick, the company asserts. The product is available on Calgenex's website for $19.95 and the firm is supporting the launch with radio ads and TV infomercials...
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.